Patents Examined by Svetlana M Ivanova
  • Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
    Patent number: 10493080
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: December 3, 2019
    Assignees: The Scripps Research Institute, Novartis AG
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • Methods of treating behavioral syndromes using pipradrol
    Patent number: 10493069
    Abstract: Methods of treating behavioral syndromes by administering a pharmaceutical composition of pipradrol or a pharmaceutically acceptable salt thereof are provided. The methods may be used to treat Attention-Deficit Disorder (ADD) and Attention-Deficit Hyperactivity Disorder (ADHD).
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: December 3, 2019
    Assignee: OVID THERAPEUTICS INC.
    Inventor: Matthew During
  • Pharmaceutical composition containing pyridylaminoacetic acid compound
    Patent number: 10485872
    Abstract: The purpose of the present invention is to provide a pharmaceutical composition that comprises a specific compound and exhibits a superior preservation efficacy, the specific compound being stable within the pharmaceutical composition, and to provide methods for improving the stability of the specific compound within the pharmaceutical composition and the preservation efficacy of the pharmaceutical composition. The pharmaceutical composition according to the present invention comprises isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and further comprises edetic acid or a salt thereof.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: November 26, 2019
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventor: Yoko Endo
  • Use of daphnoretin in prevention of tissue or organ transplant rejection or graft-versus-host-disease
    Patent number: 10478419
    Abstract: Disclosed herein are methods of using daphnoretin to treat, prevent or reduce the incidence of organ transplant rejection and graft-versus-host disease (GVHD). According to embodiments of the present disclosure, daphnoretin is administered to the recipient subject or to the donor organ prior to the transplantation to reduce immune response in the recipient subject against the transplanted organ, or to lower the risk of developing GVHD in the recipient subject.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: November 19, 2019
    Assignee: MACKAY MEMORIAL HOSPITAL
    Inventor: Yu-Jen Chen
  • Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
    Patent number: 10471049
    Abstract: Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: November 12, 2019
    Assignee: Ankh Life Sciences Limited
    Inventors: Gene H. Zaid, Thomas W. Burgoyne
  • Inhibitors of glucocorticoid receptor
    Patent number: 10472387
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: November 12, 2019
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina
  • Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
    Patent number: 10456411
    Abstract: The present invention provides a composition comprising a mixture of an exogenous ketone body, an exogenous NAD modulator and a methyl donor. Typically, exogenous NAD modulator is an exogenous nicotinamide adenine dinucleotide (NAD) precursor. The present invention also provides a method of using such a composition for treating various clinical conditions, including metabolic disorders and neurocognitive impairments. The compositions of the invention can also be used to improve human performance in various competitive or environmental conditions.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: October 29, 2019
    Assignee: Tecton Group, LLC
    Inventor: Michael A. Schmidt
  • Avibactam and carbapenems antibacterial agents
    Patent number: 10434089
    Abstract: Described are methods of treating or preventing a bacterial infection by administering an antibacterial agent comprising a ?-lactamase inhibitor and one or more carbapenem to a subject.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: October 8, 2019
    Assignee: The Johns Hopkins University
    Inventor: Gyanu Lamichhane
  • Formulations and methods for lyophilization and lyophilates provided thereby
    Patent number: 10426729
    Abstract: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: October 1, 2019
    Assignee: Biogen Chesapeake LLC
    Inventor: Sven Martin Jacobson
  • Compositions and methods for preserving red blood cells and platelets
    Patent number: 10426160
    Abstract: Blood and platelet storage and rejuvenating compositions that include triciribine, triciribine metabolites, triciribine analogs, and mixtures of the same are disclosed. Such compositions can be useful in methods for treating (e.g., storing and rejuvenating) red blood cells and platelets.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: October 1, 2019
    Assignee: RythRx Therapeutics, LLC
    Inventor: Narayanan Surendran
  • Methods and compositions for the inhibition of Pin1
    Patent number: 10413548
    Abstract: The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: September 17, 2019
    Assignees: Beth Israel Deaconess Medical Center, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kun Ping Lu, Matthew Brian Boxer, Mindy Irene Emily Davis, Rajan Pragani, Min Shen, Anton Momtchilov Simeonov, Shuo Wei, Xiao Zhen Zhou
  • Methods of treatment using a JAK inhibitor compound
    Patent number: 10406148
    Abstract: The invention relates to methods of treating ocular diseases and certain respiratory diseases using the compound 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: September 10, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melanie A. Kleinschek, Glenn D. Crater
  • Use of zoledronic acid to prepare drug treating fatty liver disease
    Patent number: 10391109
    Abstract: A method for treating fatty liver disease in a patient in need thereof, including a step of administering an effective amount of zoledronic acid. The fatty liver disease includes fatty liver disease caused by foodborne and hereditary factors, in particular non-alcoholic fatty liver. A dosage form of the zoledronic acid is an injection, a solution, a tablet, or a capsule.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: August 27, 2019
    Assignee: NANJING UNIVERSITY
    Inventors: Chaojun Li, Bin Xue, Shan Jiang, Qiaoli Tang
  • Ketorolac for the treatment of cancer
    Patent number: 10391080
    Abstract: Methods of treating cancer, including PAR-4 implicated cancers or renal cell carcinoma, using ketorolac are disclosed herein. Ketorolac can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: August 27, 2019
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
    Patent number: 10376528
    Abstract: The present invention provides a composition comprising a mixture of an exogenous ketone body, an exogenous NAD modulator and a methyl donor. Typically, exogenous NAD modulator is an exogenous nicotinamide adenine dinucleotide (NAD) precursor. The present invention also provides a method of using such a composition for treating various clinical conditions, including metabolic disorders and neurocognitive impairments. The compositions of the invention can also be used to improve human performance in various competitive or environmental conditions.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: August 13, 2019
    Assignee: TECTON GROUP, LLC
    Inventor: Michael A. Schmidt
  • Inhibition of multiple pathogenic agents using bithionol
    Patent number: 10369119
    Abstract: Compositions and methods including Bithionol are provided for treating, inhibiting, or preventing caspase-dependent pathogenic agents in a host cell or infected subject. Examples of caspase-dependent pathogenic agents include ricin, anthrax toxin, Botulinum neurotoxin A, diphtheria toxin, Pseudomonas aeruginosa exotoxin A, cholera toxin, Zika virus, and combinations thereof. Compositions and methods also include Bithionol in combination with an antibiotic for more effective clearance of the pathogen and/or toxins.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: August 6, 2019
    Assignee: Keck Graduate Institute of Applied Life Sciences
    Inventors: Mikhail Martchenko, William Leonardi
  • Compositions comprising metformin and a glucokinase activator
    Patent number: 10363244
    Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: July 30, 2019
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Maria Carmen Valcarce Lopez
  • Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of synapse function
    Patent number: 10350195
    Abstract: Compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, disclosed are combined therapies that modulate synapse function for treating the disease.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: July 16, 2019
    Assignee: Pharnext
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Oxana Guerassimenko, Nathalie Cholet
  • Composition and method for treating skin conditions
    Patent number: 10350202
    Abstract: Compositions and methods for treatment of conditions affecting skin and/or mucosal surfaces of a subject that make use of an imidazoquinoline compound and a retinoid agent are described.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: July 16, 2019
    Assignee: 442 Ventures, LLC
    Inventor: J. Mark Jackson
  • Dosing regimen for sedation with CNS 7056 (Remimazolam)
    Patent number: 10342800
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: July 9, 2019
    Assignee: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire